Lytgobi is owned by Taiho Oncology.
Lytgobi contains Futibatinib.
Lytgobi has a total of 2 drug patents out of which 0 drug patents have expired.
Lytgobi was authorised for market use on 30 September, 2022.
Lytgobi is available in tablet;oral dosage forms.
Lytgobi can be used as method of treating intrahepatic cholangiocarcinoma.
Drug patent challenges can be filed against Lytgobi from 2026-09-30.
The generics of Lytgobi are possible to be released after 31 March, 2036.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US9108973||TAIHO ONCOLOGY||3,5-disubstituted alkynylbenzene compound and salt thereof|| |
(9 years from now)
|US10434103||TAIHO ONCOLOGY||Crystal of 3,5-disubstituted benzene alkynyl compound|| |
(13 years from now)
|New Chemical Entity Exclusivity (NCE)||Sep 30, 2027|
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 2026-09-30
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic